Zymo Research Responds to Recent Court Ruling in Litigation With QIAGEN GmbH
Complete the form below to unlock access to ALL audio articles.
Zymo Research Corporation acknowledges the recent ruling, on March 14, 2025, by the United States District Court for the Central District of California in the ongoing litigation with QIAGEN GmbH. The Court has denied QIAGEN’s Partial Motion to Dismiss and, in the alternative, to stay certain counterclaims brought by Zymo Research, including claims of patent unenforceability and antitrust violations.
Zymo Research is pleased with the Court’s ruling and expects that its antitrust claims will be further vindicated through discovery and trial.
Want more breaking news?
Subscribe to Technology Networks’ daily newsletter, delivering breaking science news straight to your inbox every day.
Subscribe for FREE“We appreciate the Court’s decision, which allows Zymo to defend our innovations.” said Dr. Marc Van Eden, VP of Corporate Development.
Zymo Research remains confident in the novelty of its cfDNA MagicBead™ technology and looks forward to presenting its case as proceedings continue. This ruling reinforces Zymo Research’s commitment to protecting scientific innovation and ensuring fair competition in the biotechnology sector. As proceedings continue, the company remains focused on delivering cutting-edge sample preparation technologies to the biomedical community worldwide.
